The worldwide market for treating follicular lymphoma (FL) is steadily growing with strong and positive developments in the targeted therapies sector. It is Protheragen's objective to solve the problems surrounding the diagnosis and treatment of FL through innovative multidisciplinary approaches. As your dependable collaborator in the FL therapeutic research venture, we guarantee all scientific research services with the highest standards of quality and detail.
Follicular lymphoma (FL), a form of indolent non-Hodgkin lymphoma and is associated with B-lymphocytes. Its manifestation includes the pathological increase of lymphocytes in the lymph nodes, bone marrow, as well as other forms of lymphoid tissues. The most frequent complaints are painless lymphadenopathy, which develops in the cervical region, axilla, and inguinal region. In FL, the tumor cells are defined as centrocytes and centroblasts which can be seen microscopically in a nodular or follicular fashion.
Fig.1 Cellular morphology of grade 2 follicular lymphoma (FL). (Ortiz-Hidalgo, Carlos, and Emilio Medina-Ceballos., 2023)
Follicular lymphoma (FL) arises due to the t(14;18) translocation which results in overexpression of BCL-2, a protein that inhibits apoptosis, enabling B-cells to become cancerous. In addition to this, there are often secondary changes in epigenetic regulators such as EZH2, CREBBP, KMT2D, and immune evasion genes. The tumor microenvironment facilitates the infiltration of lymphocytes, aiding FL development through the interactions between malignant B-cells and follicular helper T-cells (TFH).
Fig.2 A schematic overview on the evolution of follicular lymphoma (FL). (Kurz, Katrin S., et al., 2023)
The global follicular lymphoma (FL) treatment market is anticipated to increase at a rate of 7.6% from USD 2.08 billion in 2019 to USD 3.73 billion by 2027, driven by advancements in medical infrastructure and the significant progress in targeted therapy development. The following are emerging therapeutic pipelines targeting FL molecules and immune vulnerabilities.
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Zevalin | Delivers targeted radiation to CD20+ cells. | CD20 | NCT00384111 | Phase III |
| Mosunetuzomab | Redirects T-cells to kill malignant B-cells. | CD20 × CD3 | NCT05529524 | Approved |
| Tazemetostat | Reverses aberrant epigenetic silencing in FL with EZH2 mutations. | EZH2 | NCT05228158 | Approved |
| YY-20394 | Induces apoptosis in malignant B-cells. | PI3Kδ | NCT04370405 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
At Protheragen, we provided integrated diagnostic and therapeutic development services to tackle complications of lymphoproliferative disorders (LPDs), such as follicular lymphoma (FL). This includes developing in vitro diagnostic (IVD) kits as well as devising nuevos therapies. Our extensive knowledge and sophisticated tools enable us to develop precise disease models which mirror the intricate nature of FL.
Protheragen takes great pride in providing integrated preclinical services for follicular lymphoma (FL). These services cover all aspects of disease research including pharmacodynamics (PD), pharmacokinetics (PK), and toxicology studies. We observe the highest quality and ethics in the execution of all our research services to make certain the outcome is dependable.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
